Evaluation of screening tests to prevent transfusion-associated non-A non-B hepatitis

Fleurette F, Durieux P
Record ID 31995000088
Authors' objectives:

To determine the optimal prevention strategy for transfusion associated non-A non-B hepatitis at the request of the French Department of Health. The expert panel defined the following issues: frequency of transfusion-associated non-A non-B hepatitis, clinical course of the disease, efficacy of surrogate and direct tests.

Authors' results and conclusions: Non-A non-B hepatitis constitutes the major transfusion-associated infection risk.50% of cases become chronic, 20% progress to cirrhosis. Surrogate tests (ALT and anti-HBc) and a direct test (anti-HCV) can be used. Only anti-HCV can decrease the incidence of transfusion-associated non-A non-B hepatitis by more than 50%. More than 80% of anti-HCV+blood samples are not detected by surrogate tests.
Authors' recommendations: Anti-HCV testing is clearly the most effective strategy, but various policies can be adopted given the uncertainties of scientific and cost data. We recommended that surrogate tests be used in addition to the anti-HCV test in all French blood banks. Other output or dissemination activity: This is the current French policy.
Authors' methods: Review
Project Status: Completed
URL for project: http://www.has-sante.fr/
Year Published: 1991
English language abstract: An English language summary is available
Publication Type: Not Assigned
Country: France
MeSH Terms
  • Blood Banks
  • Blood Transfusion
  • Hepatitis
  • Mass Screening
Organisation Name: L'Agence Nationale d'Accreditation d'Evaluation en Santé
Contact Address: 2 avenue du Stade de France, 93218 Saint-Denis La Plaine Cedex, France. Tel: +33 01 55 93 71 88; Fax: +33 01 55 93 74 35;
Contact Name: sh.leerobin@has-sante.fr
Contact Email: sh.leerobin@has-sante.fr
Copyright: Agence Nationale pour le Developpement de l'Evaluation Medicale
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.